1. Home
  2. ONDS vs CRSP Comparison

ONDS vs CRSP Comparison

Compare ONDS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ondas Holdings Inc.

ONDS

Ondas Holdings Inc.

SELL

Current Price

$6.19

Market Cap

5.6B

ML Signal

SELL

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

SELL

Current Price

$51.12

Market Cap

5.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ONDS
CRSP
Founded
2014
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.2B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
ONDS
CRSP
Price
$6.19
$51.12
Analyst Decision
Strong Buy
Buy
Analyst Count
10
23
Target Price
$18.88
★ $85.63
AVG Volume (30 Days)
★ 49.9M
1.7M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.38
N/A
Revenue
$50,731,000.00
★ $289,590,000.00
Revenue This Year
$957.99
$1,052.09
Revenue Next Year
$88.66
$273.88
P/E Ratio
$16.18
★ N/A
Revenue Growth
605.31
★ 9169.85
52 Week Low
$4.95
$44.12
52 Week High
$15.28
$75.06

Technical Indicators

Market Signals
Indicator
ONDS
CRSP
Relative Strength Index (RSI) 30.14 43.58
Support Level N/A $50.19
Resistance Level $7.98 $60.71
Average True Range (ATR) 0.34 2.58
MACD -0.10 -0.50
Stochastic Oscillator 19.81 20.43

Price Performance

Historical Comparison
ONDS
CRSP

About ONDS Ondas Holdings Inc.

Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: